70 structural-engineering "https:" "https:" "https:" "https:" "https:" "https:" "Multiple" "U.S" positions at City of Hope
Sort by
Refine Your Search
-
to immunotherapies for type 1 diabetes as well as somatic variants in the pancreas and immune cells of organ donors with type 1 diabetes. For more information on the Shapiro Laboratory please visit here: https
-
of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been
-
grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of
-
support of leukemia genomics and other biomedical research projects. The position emphasizes next-generation sequencing (NGS) data analysis, workflow development, high-performance computing, and structured
-
of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been
-
evolution. Our work builds on experience developing pangenome graph construction and analysis tools (PGGB, ODGI, IMPG) and contributions to the Telomere-to-Telomere Consortium and Human Pangenome Reference
-
Scientist must possess, at a minimum, the U.S. equivalent Bachelor’s or Master’s degree in an appropriate discipline, and will often have a Ph.D. or other doctoral level degree. Strong background in oncology
-
and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been
-
program is supported by multiple NIH (R01s), American Cancer Society, The Alex’s Lemonade Stand Foundation and several other prestigious private awards. As a successful candidate you will: · Conduct
-
: · Contribute to the development of CD38 antibody‑drug conjugates (ADCs) and other multiple myeloma targets, including monoclonal antibody (mAb) engineering, ADC conjugation, biophysical characterization (SPR